Additionally, patients with T2DM with a heavy treatment burden, have contraindications to other common anti-diabetic agents, those susceptible to hypoglycemic events, or those who refuse to initiate insulin shots, are also candidates for initiating SGLT2-inhibitors [44,45]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.